We discuss the key learnings from 151 public comment letters on the proposed Global Benchmark for Efficient Drug Pricing (GLOBE) model.
Executive takeaway
The GLOBE public comments appear materially more mixed than the GUARD comments. The center of gravity is not simple opposition to lower prices in the abstract, but the concern that a Part B reference-pricing model could disrupt office-based drug delivery, continuity of care, and the economics of buy-and-bill administration.
Background
CMS describes GLOBE as a five-year proposed model for clinician-administered drugs, with a proposed launch date of October 1, 2026, a planned end date of September 30, 2031, and comment submissions due February 23, 2026. The public-facing CMS materials frame GLOBE as a global-benchmarking model for drugs administered in clinical settings, including oncology and autoimmune therapies.
This analysis summarizes themes emerging in 151 public comments and does not take a position on the ultimate adoption of the GLOBE model.
Who commented
| Sender bucket | Count | Interpretation |
| Pharma / biotech industry | 69 | Largest block; includes manufacturers, industry associations, investor coalitions, and manufacturer-aligned submissions. |
| Patient access / advocacy | 37 | Disease foundations, patient organizations, and patient-oriented coalitions focused on access and continuity of care. |
| Provider / pharmacy / distribution | 21 | Practices, provider associations, pharmacists, distributors, and operational trade groups. |
| Public policy / think tank / academic | 13 | Policy institutes, public-interest groups, research entities, and academic centers. |
| All others | 11 | Residual items, exhibits, individuals, and anonymous submissions. |
Although CMS frames GLOBE as a global benchmarking model, stakeholder responses focus largely on its downstream operation as a Part B reference‑pricing mechanism for physician‑administered drugs.
The makeup of the file matters because it helps explain the tone of the comments. GLOBE drew the largest response from industry, but it also drew a substantial number of access-focused organizations and a meaningful operational bloc from provider, pharmacy, and distribution stakeholders. That mix is consistent with a model that directly touches the care-delivery channel for physician-administered drugs.
Overall tenor of the GLOBE file
| Stance | Count | Read across the file |
| Negative | 63 | Letters arguing GLOBE should be withdrawn, substantially narrowed, or viewed as likely to produce significant harm. |
| Neutral / mixed | 82 | Letters that acknowledge GLOBE’s affordability goals but focus on technical concerns, guardrails, or implementation changes. |
| Positive | 6 | Clearly supportive letters, usually coupled with requests for beneficiary protections or implementation detail. |
As with all notice‑and‑comment records, the file reflects self‑selected participation and likely overrepresents stakeholders with the greatest economic exposure.
The strongest single conclusion from the GLOBE file is that the model produced a far larger middle category than GUARD. Instead of near-uniform rejection, many GLOBE comments take a conditional posture: they support the goal of reducing drug costs, but warn that the proposed design could destabilize care delivery unless CMS adds guardrails, clarifies operations, and protects access for medically fragile populations.
The five core themes
- Patient access and continuity of care dominate the responses. Many commenters frame GLOBE as a risk to in-office treatment availability, continuity for stable patients, and access to specialty-administered therapies.
- Operational burden is central. Compared with GUARD, GLOBE comments spend much more time on provider reimbursement, buy-and-bill economics, specialty distribution, reimbursement lags, and the mechanics of drug administration in physician practices.
- Innovation concerns remain important, but they are often tied to the specific product classes affected by Part B-style administration, including oncology, infused biologics, and rare-disease treatments.
- Legal-authority arguments are still present, but they are less dominant than in GUARD. The GLOBE comment file is driven more by practical delivery concerns than by pure statutory attack.
- Rare-disease and orphan-drug protections are a recurring modification request, especially where commenters argue there are few substitutes and a high risk of treatment disruption.
Buy-and-bill is a defining GLOBE issue
One of the most important lessons from the GLOBE letters is that provider concern is not best understood as a simple complaint about lower margins. The more substantial argument is that the model could create a mismatch between reimbursement benchmarks and actual acquisition costs for physician-administered drugs. Once practices are forced “underwater” on drug acquisition, it becomes an access and care-delivery issue in addition to financial risk.
- Practices may become less willing to stock or administer affected therapies in-office.
- Patients may be shifted to white bagging, specialty-pharmacy channels, or hospital outpatient departments.
- Site-of-care shifts can increase patient inconvenience, administrative burden, and, in some scenarios, total out-of-pocket exposure, depending on benefit design, supplemental coverage, and site‑specific coinsurance rules.
- Operational instability can produce treatment delays, disruptions in continuity of care, and reduced local availability of infused or injected therapies.
This is why buy-and-bill deserves to be treated as more than a sub-issue inside a generic “implementation” section. It is one of the clearest substantive differences between the GLOBE and GUARD comment records. GUARD raised more questions about manufacturer liability and Part D mechanics. Whereas, GLOBE raises more questions about whether office-based drug delivery remains financially and operationally viable under the proposed benchmark design.
Requested modifications
- Add beneficiary protections and continuity-of-care safeguards for stable patients already receiving therapy.
- Protect physician practices and other providers from acquisition-cost and reimbursement mismatches that would destabilize buy-and-bill administration.
- Exclude or specially protect orphan and rare-disease therapies, plasma-derived products, and other medically sensitive categories with few substitutes.
- Clarify interaction with 340B, specialty pharmacy distribution, reimbursement timing, inventory risk, and other federal pricing mechanisms.
- Phase implementation more cautiously and publish more operational detail before launch.
Implications for CMS
The GLOBE comments suggest that the model will be judged less on whether it delivers savings based on international price benchmarking and more on whether it can preserve care delivery in the domestic provider setting. If CMS wants to improve the model’s prospects, the comments point toward a narrower and more operationally guarded version of GLOBE: stronger patient protection, a more credible strategy for managing buy-and-bill consequences, and clearer pathways for specialty and rare-disease therapies.
To discuss how you can realign your price governance model to meet MFN-led shifts in the industry, reach out to our experts.
